Boston Scientific

NATICK, Massachusetts, May 12, 2010 - Boston Scientific Corporation (NYSE: BSX) today announced it has received CE Mark approval for its TAXUS(R) Element(TM) Paclitaxel-Eluting Coronary Stent System, the Company's third-generation drug-eluting stent (DES) technology.

NATICK, Massachusetts and BARCELONA, Spain - - Results of Landmark Heart Failure Trial Published by New England Journal of Medicine and Presented at ESC Boston Scientific Corporation (NYSE: BSX) today announced final results from the landmark MADIT-CRT trial, which were published by the New England Journal of Medicine and presented during a Hot Line session at the annual European Society of Cardiology (ESC) Congress in Barcelona.